source
- Amgen defends Tavneos as FDA, European regulators and Japanese doctors raise safety concernsAmgen said it continues to support its rare-disease therapy Tavneos despite recent safety alerts. The U.S. FDA has indicated it wants the drug removed from the market after a report of 20 deaths l…
- China's rapid drug development fuels split among U.S. biotech firmsDamian Garde spoke with more than a dozen investors, entrepreneurs and industry leaders about how China's growing role is reshaping U.S. biotech strategy. American companies have poured roughly $6…